TOLREMO therapeutics
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
5,011Activities
Technologies
Entity types
Location
Hochbergerstrasse 60C, 4057 Basel, Switzerland
Basel
Switzerland
Employees
Scale: 11-50
Estimated: 14
Engaged corporates
2
0 2Added in Motherbase
1 year, 1 month ago
biotech Value proposition
Stopping non-genetic cancer drug resistance as it emerges
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.
Drug Discovery, Drug Development, Cancer Drug Resistance, Non-genetic Cancer Drug Resistance, and Biotech
TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.
https://www.tolremo.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Other 11 May 2024 | | |
 Pierre Fabre Laboratories Pharmaceutical, Pharmaceutical Manufacturing | Pierre Fabre Laboratories Pharmaceutical, Pharmaceutical Manufacturing | Other 19 Sep 2023 | | |